SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo
DE Griswold, EF Webb, AM Badger, PD Gorycki… - The Journal of …, 1998 - Elsevier
The ability of the second generation phosphodiesterase 4 inhibitor SB 207499 (Ariflo),[c-4-
cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-rl-cyclohexane carboxylic acid], to inhibit
inflammatory cytokine production in vivo was evaluated and compared to that of rolipram, a
first generation phosphodiesterase 4 inhibitor. To examine human tumor necrosis factor
alpha (TNFα) production, human monocytes were adoptively transferred into Balb/c mice
and challenged with lipopolysaccharide (LPS). In this model, SB 207499 inhibited human …
cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-rl-cyclohexane carboxylic acid], to inhibit
inflammatory cytokine production in vivo was evaluated and compared to that of rolipram, a
first generation phosphodiesterase 4 inhibitor. To examine human tumor necrosis factor
alpha (TNFα) production, human monocytes were adoptively transferred into Balb/c mice
and challenged with lipopolysaccharide (LPS). In this model, SB 207499 inhibited human …